Anti-SARS-COV-2 specific immunity in HIV immunological non-responders after mRNA-based COVID-19 vaccinationArticle Published on 2022-08-262022-11-15 Journal: Frontiers in Immunology [Category] SARS, 진단, [키워드] antibody booster vaccination CD4 cell Cellular immune response Cohort control group correlated COVID-19 COVID-19 vaccination disease FIVE Follow-up healthy individual HIV HIV-1 Human immunodeficiency virus immune immune response immune responses Immunity immunological immunological non-responder (INR) Immunosuppression individual lack mRNA-based non-responder Patient receive receiving SARS-CoV-2 SARS-COV-2 infection vaccinated against COVID-19 Vaccine [DOI] 10.3389/fimmu.2022.994173 PMC 바로가기
Immunologic phenotype of patients with long-COVID syndrome of 1-year durationArticle Published on 2022-08-242022-11-15 Journal: Frontiers in Immunology [Category] SARS, 치료기술, [키워드] 95% confidence interval Adjusted analysis adjusted hazard ratio analyzed antibody Antibody Response antibody response, antinuclear antibodies (ANA) Autoimmunity Biomarker blood sample C-reactive protein cellular Cellular immune response cellular immune responses chronic inflammation COVID-19 COVID-19 symptom D-dimer detectable discharged Follow-up Frequency groups hospital hospitalized COVID-19 patient humoral humoral immune response ICU admission immune immune response Immunologic include Inflammation information Level Long COVID long-COVID mitigate myalgia neutralizing antibody no difference not different One year pathophysiology Patient phenotype positive Post-COVID-19 syndrome Prospective questionnaire reported SARS-CoV-2 antibody serological Smokers Symptom symptomatic patient Symptomatic patients syndrome T-cell T-cell immune response WHO severity score women [DOI] 10.3389/fimmu.2022.920627 PMC 바로가기
Serum peptidome profiles immune response of COVID-19 Vaccine administrationArticle Published on 2022-08-242022-11-15 Journal: Frontiers in Immunology [Category] SARS, 바이오마커, 진단, [키워드] activated acute respiratory syndrome administration Analysis analyzed Antigen Biomarker C1q caused CD59 CD99 Cellular immune response clinical trials collected Complete CoronaVac coronavirus Coronavirus disease 2019 COVID-19 COVID-19 vaccination COVID-19 vaccine Efficacy Evidence glycoprotein help hemoglobin humoral immune immune response immunization immunogenicity analysis individual information Laboratory linear Logistic regression MALDI-TOF membrane protein NAb neutralizing antibody pandemic participant peptide peptides Peptidome performed Platelet profile Protein provided random receiving receptor reported Research SARS-CoV-2 serum serum sample Significant statistical analysis subunits Support SVM vaccination Vaccine Vaccines [DOI] 10.3389/fimmu.2022.956369 PMC 바로가기
Squalene in oil-based adjuvant improves the immunogenicity of SARS-CoV-2 RBD and confirms safety in animal models오일 기반 보조제의 스쿠알렌은 SARS-CoV-2 RBD의 면역원성을 개선하고 동물 모델에서 안전성을 확인합니다Article Published on 2022-08-232022-09-11 Journal: PLoS ONE [Category] SARS, 변종, 진단, 치료기술, [키워드] accelerated adjuvant Analysis animal model assays binding Cellular immune response Chromatography conditions COVID-19 demonstrated determine determined by elicited ELISA etiologic agent evaluated expressed flow cytometry Formulation hamsters histopathological humoral immune immunization immunogenicity IMPROVE insect cell insect cells kidney lead liver Lungs mice Neutralizing antibodies neutralizing antibody pandemic Protein purified RBD of SARS-CoV-2 RBD protein receptor Safe SARS-CoV-2 SARS-CoV-2 RBD sera shown squalene stimulate sub-unit vaccine the Spike Vaccine vaccine candidate variant virus water [DOI] 10.1371/journal.pone.0269823 PMC 바로가기 [Article Type] Article
Heterogenous humoral and cellular immune responses with distinct trajectories post-SARS-CoV-2 infection in a population-based cohort인구 기반 코호트에서 SARS-CoV-2 감염 후 뚜렷한 궤적을 가진 이종 체액성 및 세포성 면역 반응Article Published on 2022-08-182022-09-11 Journal: Nature Communications [Category] SARS, 변종, 진단, 치료기술, 치료법, [키워드] Analysis anti-N IgG anti-S responses antibody Antibody responses Cellular immune response cellular immunity cellular response characterized clinical factors Cluster analyses Delta detectable develop Diagnosis FIVE heterogeneity humoral humoral and cellular immunity Humoral and cellular responses identify IgA IgG immune Immunity individual infected individuals Infection maintain membrane Neutralizing activity neutralizing antibody omicron Omicron variants Participants population-based cohort required responses S proteins SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2-infected individual T cell T cell response T cell responses T cells trajectory variant [DOI] 10.1038/s41467-022-32573-w PMC 바로가기 [Article Type] Article
Evaluation of safety and immunogenicity of receptor-binding domain-based COVID-19 vaccine (Corbevax) to select the optimum formulation in open-label, multicentre, and randomised phase-1/2 and phase-2 clinical trialsClinical Trial Published on 2022-08-122022-10-05 Journal: EBioMedicine [Category] SARS, 변종, 임상, 진단, [키워드] adverse event Anti-RBD IgG AstraZeneca baseline Biotechnology Cellular immune response cellular immune responses clinical clinical trial Coalition conducted convalescent serum correlation COVID-19 COVID-19 vaccination COVID-19 vaccine CpG1018 Department domain doses Efficacy finding foundation funding groups humoral immune responses incidence India Innovation Melinda Gate Moderna multicentre NAb neutralising antibody observation Open-label profile Protein subunit randomised randomly divided Receptor-binding domain Registered registry reported safety profile SARS-CoV-2 SARS-COV-2 infection second dose significantly Spike protein the vaccine titre titres Trial Vaccine [DOI] 10.1016/j.ebiom.2022.104217 [Article Type] Clinical Trial
Immunogenicity of BNT162b2 COVID-19 vaccine in New Zealand adults뉴질랜드 성인에서 BNT162b2 COVID-19 백신의 면역원성Article Published on 2022-08-122022-09-11 Journal: Vaccine [Category] COVID19(2023년), MERS, SARS, 변종, 진단, [키워드] age All participant All participants analysed anti-S IgG Antibody Response baseline Beta BMI BNT162b2 BNT162b2 mRNA vaccine BNT162b2 vaccine Cellular immune response cellular immune responses co-morbidities Cohort COVID-19 COVID-19 disease COVID-19 vaccine declined Delta diabete diabetes diabetics disease dose enrichment Ethnic groups female Gender General population IgG immune response immune responses immunoassay immunogenicity in vitro International Lower Māori median age Microparticle morbidities morbidity naïve neutralise neutralising antibody neutralising response neutralising responses neutralizing capacity New obesity of BNT162b2 Older Older adults omicron other variant other variants Pacific Islander Population prospective cohort study pulmonary disease Quantitative recipient representation response risk robust SARS-CoV-2 vaccine second dose second vaccination serious COVID-19 seroconverted serum sample serum samples strain the vaccine Vaccine variant Viral viral neutralisation Wuhan [DOI] 10.1016/j.vaccine.2022.07.009 PMC 바로가기 [Article Type] Article
Comparative immunogenicity and reactogenicity of heterologous ChAdOx1-nCoV-19-priming and BNT162b2 or mRNA-1273-boosting with homologous COVID-19 vaccine regimens Research Published on 2022-08-112022-10-05 Journal: Nature Communications [Category] SARS, 치료기술, [키워드] Analysis Antigen BNT162b2 CD4 T-cell CD8 T-cell Cellular immune response ChAdOx1-nCoV-19 Cohort Combination combinations Comparative COVID-19 vaccine FIVE healthy individuals Heterologous highest homologous humoral Immunity induce mRNA-1273 reactogenicity regimen regimens SARS-CoV-2 T-cell the vaccine vaccination Vaccination strategy Vaccine [DOI] 10.1038/s41467-022-32321-0 [Article Type] Research
Strong T-cell activation in response to COVID-19 vaccination in multiple sclerosis patients receiving B-cell depleting therapiesB 세포 고갈 요법을받는 다발성 경화증 환자에서 COVID-19 예방 접종에 대한 강력한 T 세포 활성화Article Published on 2022-08-052022-09-11 Journal: Frontiers in Immunology [Category] SARS, 바이오마커, 치료기술, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 adaptive Adaptive immune response Adaptive immunity analyzed anti-CD20 anti-CD20 therapy antibodies antibody production B-cell binding blocking activity BNT162b2 Cellular immune response cellular response Cohort competent Complication condition controls coronavirus COVID-19 COVID-19 vaccination depleting disease driven by form forms hACE2 healthy control humoral Humoral and cellular responses IFNγ IgG antibodies IgG antibody IL-2 immunocompromised individuals Immunotherapy implication individual individuals Infection investigation mRNA mRNA-1273 mRNA-based mRNA-based vaccine multiple sclerosis no difference Ocrelizumab Patient patients proliferation RBD receiving Receptor binding domain recognizing reduced regimen relapsing respiratory rituximab SARS-CoV-2 Seroconversion seroconversion rate severe acute respiratory syndrome Coronavirus significantly significantly higher Spike protein Strong strong T-cell susceptible T-cell T-cell activation T-cell Response therapy vaccination Vaccine design virus infection [DOI] 10.3389/fimmu.2022.926318 PMC 바로가기 [Article Type] Article
Homotypic and heterotypic immune responses to Omicron variant in immunocompromised patients in diverse clinical settings다양한 임상 환경에서 면역 저하 환자의 오미크론 변이체에 대한 동형 및 이형 면역 반응Article Published on 2022-08-042022-09-11 Journal: Nature Communications [Category] SARS, 변종, 유전자 메커니즘, 진단, 치료기술, 치료법, [키워드] CD4 CD8 Cellular immune response clinical setting comparable controls cross-neutralization D614G Delta Delta variants disease severity dose Host humoral identify immune immune response immune responses Immunocompromised Immunocompromised patient Immunocompromised patients implication Infection magnitude neutralization neutralizing antibody omicron Organ transplant Patient patients peptide peptide pools Pseudovirus neutralization assay Re-infection recipient response responses risk of infection SARS-CoV-2 severe COVID-19 subset T-cell Response T-cell responses uninfected Vaccine variant variants [DOI] 10.1038/s41467-022-32235-x PMC 바로가기 [Article Type] Article